Description of Valgan
Valgan (Valganciclovir) is an anti viral agent used to prevent Cytomegalovirus infection, which occurs after organ transplantation. Valganciclovir also involved in the treatment of CMV eye infection which is occurred in AIDS patient. Active ingredient: valganciclovir Brand: Valgan 400mg Mfg: Cipla Dosage form: tablet
Pharmacology of Valgan
Valgan (Valganciclovir) is a prodrug (L-valyl ester) of Ganciclovir, it prevails as two diastereomers. Valgan, on oral administration, both the diastereomers are changed to Ganciclovir by intestinal and hepatic esterases. Valgan (Ganciclovir) is an active form; it is deoxyguanosine analogue, which prohibits multiplication of human cytomegalovirus cell culture. Pharmacokinetic: Absorption: Valgan is well absorbed in GI tract, and the bioavailability of Ganciclovir is over 60%. Distribution: The plasma protein binding of Ganciclovir is 1-2% Metabolism: Valganciclovir is highly metabolized into Ganciclovir. Elimination: The drug after metabolization is greatly excreted through renal. The half life of Ganciclovir is 6.48 ± 1.38 hours. Indications: Valgan is indicated for adult patient; CMV retinitis: Tablet Valgan is mainly indicated for the treatment of CMV retinitis (eye infection) in HIV patients.
Indication of Valgan
Valgan is indicated for adult patient; CMV retinitis: Tablet Valgan is mainly indicated for the treatment of CMV retinitis (eye infection) in HIV patients.
Dose & Dosage's of Valgan
Valgan tablet is taken orally with food. The bioavailability of the active form of valganciclovir (Ganciclovir) is significantly high when compared to the Ganciclovir capsules. CMV retinitis: Initial: the prescribed dose is 900mg twice daily for 21 days. Maintenance: after induction therapy, dose followed as 900mg as a single dose. Prevention of CMV disease: After heart, or kidney-pancreas transplant, the recommended dose is 900mg as a single dose which starts with 10days of transplantation continuously for 100 days post-transplantation. For kidney transplant, 900mg once a day continuously for 200 days post transplantation.
Side Effects of Valgan
A serious adverse effect occurs during the therapy of Tablet Valgan; Hematologic adverse events Acute renal failure Diarrhea Pyrexia Hypertension Upper respiratory tract infection Nausea, vomiting Tremor Neutropenia Anemia Thrombocytopenia Headache Peripheral neuropathy Insomnia Paresthesia Retinal detachment
Contraindication of Valgan
Valgan tablet is contraindicated to the patient having anaphylactic reactions to valganciclovir, Ganciclovir
Drug Interaction of Valgan
Drug - Drug interaction occurred with Ganciclovir; Zidovudine Probenecid Mycophenolate mofetil Didanosine
Precaution of Valgan
Care should be taking Valgan tablet, if patient with pre-existing cytopenias and who are receiving myelosuppressive drugs or radiation. Hematologic toxicity Impairment of fertility Foetal toxicity Mutagenesis and carcinogenesis Acute renal failure
Usage & Safety profile of Valgan Pregnancy & Lactation
Valgan tablet is not preferred for pregnant women. Pregnancy category: D
Storage of Valgan
The storage of tablet Valgan is at room temperature (below 25oC). Keep away from moisture, heat, and light.